Before the battle for market share gets started, the courtroom is the OK Corral for biosimilar developers and reference product manufacturers, who duke it out over patents to determine how soon biosimilars can enter the marketplace. The Center for Biosimilars spoke with Alexandra Valenti, JD, and Rob Cerwinski, JD, Goodwin Intellectual Property partners and senior editors of the updated Guide to Biosimilars Litigation and Regulation in the US about some of the key developments. Listen to episode here.